ETD001, Enterprise Therapeutics’ inhaled investigational therapy to improve mucus clearance in people with cystic fibrosis (CF) —…
Articles by Steve Bryson, PhD
Biomx is ending a Phase 2b trial of BX004, its investigational nebulized phage therapy for Pseudomonas aeruginosa infection…
Adults with cystic fibrosis (CF) who are not eligible for Kaftrio therapy reported feeling forgotten in both the…
Treatment with the antibiotic azithromycin improves breathing while slowing lung function decline over time in children and teens with…
Researchers have developed nanoparticles that can deliver gene-editing therapeutics to correct genetic defects in the lungs of people with…
A University of Iowa biomedical researcher was awarded the Yergin-New International Prize for his work in understanding cystic fibrosis…
Among methods used to diagnose cystic fibrosis (CF) in France, newborn screening (NBS) was associated with the lowest healthcare…
Scientists have discovered a potential therapy for cystic fibrosis (CF) patients who are infected with Mycobacterium abscessus, a bacterium that…
A personalized inhaled phage therapy targeting multidrug-resistant lung infections significantly reduces bacterial load and improves lung function in adults with…
Ivacaftor, a component of the triple-combination therapy Trikafta, is essential to restore mucus clearance in people with…